Use of a tumor-naive MRD assay increased the accuracy of detecting ctDNA after chemotherapy treatment, when a significant drop of ctDNA amount is expected compared to tests routinely used in metastatic disease. Pre-surgery ctDNA dynamics were prognostic with respect to relapse-free survival and may help stratify patients' prognosis prior resection, potentially informing personalized treatment decisions.
Moretto et al. (Mon,) studied this question.